Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Next-Generation Therapies in CRPC Take Aim at AR Resistance

April 19th 2017

As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.

Dreicer Discusses Emerging Agents in mCRPC

April 15th 2017

Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer.

Dr. Higano on Docetaxel for Hormone-Sensitive Prostate Cancer

April 14th 2017

Celestia Higano, MD, professor of Medicine and Urology, University of Washington, member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results of docetaxel (Taxotere) versus hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

AR-V7 Predicts Response in Castration-Resistant Prostate Cancer

April 12th 2017

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.

Dr. Yu on Trials of Moderate Hypofractionation in Prostate Cancer

April 12th 2017

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

USPSTF Could Drop Its Opposition to Routine Prostate Cancer Screening

April 11th 2017

The US Preventive Services Task Force may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.

Dr. Slovin on Immunotherapy Agents for Prostate Cancer

April 11th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses potential immunotherapy agents for patients with prostate cancer.

New Checkpoint Inhibitor Approach Proposed in Prostate Cancer

April 7th 2017

Padmanee Sharma, MD, PhD, discusses the significance of the VISTA immune-checkpoint pathway in prostate cancer, and her proposed novel immunotherapy approach for patients with these tumors.

Prostate Cancer Advances Include Potential for PARP Inhibitors

April 6th 2017

Celestia Higano, MD, discusses the early use of chemotherapy, the potential for PARP inhibitors, and the evolving role of radium-223 in prostate cancer.

Dr. Dicker on the Impact of Genetic Testing for Prostate Cancer

April 5th 2017

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Expert Discusses QoL Benefits of Active Surveillance for Low-Risk Prostate Cancer

March 29th 2017

Daniel A. Barocas, MD, discusses the benefits of active surveillance in patients with low-risk prostate cancer.

In Prostate Cancer, Moderate Hypofractionation Could Be New Standard

March 28th 2017

James B. Yu, MD, discusses results of a study on moderate hypofractionation in patients with prostate cancer, as well as recent data demonstrating how genomic testing can be helpful in postoperative treatment decision making.

Crawford Highlights Role of Degarelix in Prostate Cancer

March 24th 2017

E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.

Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer

March 24th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Expert Discusses State of Immunotherapy in Prostate Cancer

March 23rd 2017

Susan F. Slovin, MD, PhD, discusses the current state of immunotherapy in prostate cancer.

Dr. Slovin on the Role of Immunotherapy for Prostate Cancer

March 22nd 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Dr. Abida on Genetic Testing for Prostate Cancer

March 21st 2017

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC Success

March 14th 2017

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Researchers Aim to Further Enhance Value of RT in Prostate Cancer

March 14th 2017

Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.

Dr. Araujo on Emerging Data on Radium-223 for Patients With mCRPC

March 13th 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.